Biomolecules (Sep 2023)

Circulating Small Extracellular Vesicles Reflect the Severity of Myocardial Damage in STEMI Patients

  • Marta Zarà,
  • Andrea Baggiano,
  • Patrizia Amadio,
  • Jeness Campodonico,
  • Sebastiano Gili,
  • Andrea Annoni,
  • Gianluca De Dona,
  • Maria Ludovica Carerj,
  • Francesco Cilia,
  • Alberto Formenti,
  • Laura Fusini,
  • Cristina Banfi,
  • Paola Gripari,
  • Calogero Claudio Tedesco,
  • Maria Elisabetta Mancini,
  • Mattia Chiesa,
  • Riccardo Maragna,
  • Francesca Marchetti,
  • Marco Penso,
  • Luigi Tassetti,
  • Alessandra Volpe,
  • Alice Bonomi,
  • Giancarlo Marenzi,
  • Gianluca Pontone,
  • Silvia Stella Barbieri

DOI
https://doi.org/10.3390/biom13101470
Journal volume & issue
Vol. 13, no. 10
p. 1470

Abstract

Read online

Circulating small extracellular vesicles (sEVs) contribute to inflammation, coagulation and vascular injury, and have great potential as diagnostic markers of disease. The ability of sEVs to reflect myocardial damage assessed by Cardiac Magnetic Resonance (CMR) in ST-segment elevation myocardial infarction (STEMI) is unknown. To fill this gap, plasma sEVs were isolated from 42 STEMI patients treated by primary percutaneous coronary intervention (pPCI) and evaluated by CMR between days 3 and 6. Nanoparticle tracking analysis showed that sEVs were greater in patients with anterior STEMI (p = 0.0001), with the culprit lesion located in LAD (p = 0.045), and in those who underwent late revascularization (p = 0.038). A smaller sEV size was observed in patients with a low myocardial salvage index (MSI, p = 0.014). Patients with microvascular obstruction (MVO) had smaller sEVs (p p = 0.039). sEV size and CD41–CD61 expression were independent predictors of MVO/MSI (OR [95% CI]: 0.93 [0.87–0.98] and 0.04 [0–0.61], respectively). In conclusion, we provide evidence that the CD41–CD61 expression in sEVs reflects the CMR-assessed ischemic damage after STEMI. This finding paves the way for the development of a new strategy for the timely identification of high-risk patients and their treatment optimization.

Keywords